Springfield Clinic | Clinical Research Department

Research site

(Unclaimed)

Location

900 N First St Rm 1104, Springfield, Illinois, United States of America

Site insights

Top conditions

Top treatments

Paclitaxel

Nivolumab

Cisplatin

Carboplatin

Atezolizumab

Pembrolizumab

Lenalidomide

Docetaxel

Gemcitabine Hydrochloride

Ibrutinib

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

12 of 199 total trials

A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Have a History of Inadequate Response to or Intolerance to at Least One Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy (KEEPsAKE 1)

The purpose of this study is to compare the safety and efficacy of risankizumab versus placebo in participants with moderately to severely active pso...

Active, not recruiting

Psoriatic Arthritis

Biological: Placebo

Biological: Risankizumab

A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis Including Those Who Have a History of Inadequate Response or Intolerance to Biologic Therapy(Ies) (KEEPsAKE2)

The purpose of this study is to evaluate the safety and efficacy of risankizumab in adults with moderately to severely active psoriatic arthritis (Ps...

Active, not recruiting

Psoriatic Arthritis (PsA)

Biological: Placebo

Biological: Risankizumab

A Study of Tiragolumab Plus Atezolizumab Compared With Placebo Plus Atezolizumab in Participants With Completely Resected Non-small Cell Lung Cancer Who Have Received Adjuvant Platinum-based Chemotherapy (SKYSCRAPER-15)

The purpose of this study is to evaluate the efficacy and safety of tiragolumab plus atezolizumab compared with placebo plus atezolizumab administere...

Enrolling

Non-small Cell Lung Cancer (NSCLC)

Drug: Atezolizumab

Drug: Placebo

A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. Non-small cell lung cancer (NSCLC) is a solid tumor,...

Enrolling

Non Small Cell Lung Cancer

Drug: Docetaxel

Biological: Telisotuzumab Vedotin

A Study to Customize Ibrutinib Treatment Regimens for Participants With Previously Untreated Chronic Lymphocytic Leukemia (TAILOR)

The purpose of this study is to evaluate the efficacy and safety of ibrutinib + venetoclax (I+V) and ibrutinib monotherapy regimens in which dosing o...

Enrolling

Small Lymphocytic Lymphoma

Leukemia, Lymphocytic, Chronic, B-Cell

Drug: Venetoclax

Drug: Ibrutinib

A Trial of Setanaxib in Patients With Primary Biliary Cholangitis (PBC) and Liver Stiffness (TRANSFORM)

The primary objective of this study is to evaluate the effect of setanaxib on alkaline phosphatase (ALP) at Week 24 in participants with PBC and with...

Active, not recruiting

Liver Stiffness

Primary Biliary Cholangitis

Drug: Placebo

Drug: Setanaxib

Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease (CIRCULATE-US)

This Phase II/III trial will evaluate the what kind of chemotherapy to recommend to patients based on the presence or absences of circulating tumor D...

Enrolling

Stage III Colon Cancer

Drug: mFOLFOX6 3-6 month

Device: Signatera test

Eversense® Non-adjunctive Use Post Approval Study (NA-PAS)

This is a non-blinded, prospective, multi-center, single arm longitudinal cohort study (patient serving as their own control), to evaluate the effect...

Enrolling

Diabetes

Device: Blood glucose meter

Device: Eversense CGM System

Pivotal 1 Study of RGX-314 Gene Therapy in Participants With nAMD (ATMOSPHERE)

RGX-314 is being developed as a novel one-time gene therapy for the treatment of neovascular (wet) age-related macular degeneration (wet AMD). Wet AM...

Enrolling

Wet Age-related Macular Degeneration

Wet AMD

Genetic: RGX-314

Biological: Ranibizumab (LUCENTIS®)

T-DM1 and Tucatinib Compared With T-DM1 Alone in Preventing Relapses in People With High Risk HER2-Positive Breast Cancer, the CompassHER2 RD Trial

This phase III trial studies how well trastuzumab emtansine (T-DM1) and tucatinib work in preventing breast cancer from coming back (relapsing) in pa...

Enrolling

Prognostic Stage IA Breast Cancer AJCC v8

Prognostic Stage IB Breast Cancer AJCC v8

Other: Questionnaire Administration

Other: Quality-of-Life Assessment

Testing the Use of A Single Drug (Olaparib) or the Combination of Two Drugs (Cediranib and Olaparib) Compared to the Usual Chemotherapy for Women With Platinum Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

This phase III trial studies olaparib or cediranib maleate and olaparib to see how well they work compared with standard platinum-based chemotherapy...

Active, not recruiting

Recurrent Primary Peritoneal Carcinoma

Ovarian Undifferentiated Carcinoma

Drug: Gemcitabine

Drug: Cediranib Maleate

Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive Meningiomas

This phase II trial studies how well vismodegib, focal adhesion kinase (FAK) inhibitor GSK2256098, and capivasertib work in treating patients with me...

Enrolling

Recurrent Meningioma

NF2 Gene Mutation

Drug: Abemaciclib

Drug: Vismodegib